Evaluation of the New Laser PHOTOLASE PLV-585nm for the Treatment of Rosacea

Inclusion Criteria: * Fitzpatrick Skin Type I - III * Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrolment and during the entire course of the study. * Clinical diagnosis of Erythematotelangiectatic Rosacea stade II * Homogeneous extend and staining telangiectasia in each half face * Patient never treated with laser for Rosacea * Patient doesn't wish to use systemic corticosteroids or retinoids; or topical corticosteroids or retinoids on the treated area. * Patient agreeing to have limited exposure to the sun and use of a protective screen (index 50 or higher) every day of the study and throughout its duration if it takes place from May to September. * Patient must be able to read, understand and sign the Informed Consent Form * Patient able to adhere to the program of visits of the study and the other imperatives of the protocol * Patient accepting to have photographs taken on the face * Quality of social insurance or social security entitlement Exclusion Criteria: * Pregnant and/or breastfeeding woman or childbearing age without effective contraception * Alcohol abuse assessed at the discretion of the investigator * History of prior laser or light based procedures for any other pathology for the face within 6 months of study participation Fitzpatrick Type IV à VI * Systemic use of isotretinoin in the 6 months prior to inclusion in the study. * Topical use of retinoids and / or corticosteroids in the 4 weeks prior to inclusion in the study. * Patient under photo sensitization treatment * Patient suffering from significant concurrent illness such as type 1 diabetes, cardiovascular disease, uncontrolled hypertension, neurological disease, lupus erythematosus, scleroderma. * Patient subject to hypertrophic or abnormal scarring * Patient presenting or having a malignant tumor or skin cancer in the area to be treated. * Having a known anticoagulative condition or taking prescription anticoagulation medications. * Participation to another clinical study involving a laser or drug within three months of inclusion in the study. * Smoker or former smoker in the 12 months prior to inclusion in the study. * Patient with excessive tattoos in the area to be treated and / or wishing to tattoo the treated area during the study. * Patient treated for cancer by chemotherapy or radiotherapy * Patient with hyper or hypo pigmentation * Patient unable to understand protocol or give consent * Legal incapacity (persons deprived of their liberty or under guardianship or curatorship) * Patient in emergency or in detention * Clinical follow-up impossible for psychological, family matters, social or geographical reasons